Literature DB >> 21794811

[Adverse effects of bisphosphonates].

Luis Arboleya1, Mercedes Alperi, Sara Alonso.   

Abstract

Aminobisphosphonates are drugs that have been used successfully in the treatment of osteoporosis for more than 20 years. Although main registry studies found a scarcity of relevant adverse events, in recent years and as a result of pharmacovigilance, different complications have been reported, some potentially serious. This has raised questions on the safety of these drugs, especially in high doses, like those used in oncology and long-term treatment, as needed in patients with osteoporosis. In this review, based on the analysis of relevant scientific evidence from clinical trials, case series, cohort studies and databases published to date, we summarize the clinical and epidemiological characteristics of the adverse effects of these drugs.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21794811     DOI: 10.1016/j.reuma.2010.10.005

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  2 in total

1.  Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.

Authors:  Jianguo Tao; Venkat Srinivasan; Xiangjiao Yi; Yingchun Zhao; Hengwei Zhang; Xi Lin; Xichao Zhou; Brendan F Boyce; Peter W Villalta; Frank H Ebetino; Koc Kan Ho; Robert K Boeckman; Lianping Xing
Journal:  J Bone Miner Res       Date:  2022-01-22       Impact factor: 6.390

Review 2.  Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity.

Authors:  Orsolya Rusz; Zsuzsanna Kahán
Journal:  Pathol Oncol Res       Date:  2012-12-05       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.